# Povetacicept PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/povetacicept

> The PDUFA target action date for povetacicept, sponsored by VERTEX PHARMACEUTICALS INC / MA (VRTX), is November 30, 2026, for immunoglobulin A nephropathy. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, half-year only, month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the povetacicept PDUFA date?

The PDUFA target action date for povetacicept, sponsored by VERTEX PHARMACEUTICALS INC / MA (VRTX), is November 30, 2026, for immunoglobulin A nephropathy. Status: scheduled. Press release filed with the SEC (EX-99): "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." Last confirmed November 13, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/povetacicept)

Source: Press release filed with the SEC (EX-99), accession 0000875320-26-000287, https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/povetacicept#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | povetacicept |
| Codes | ALPN-303 |
| Sponsor | VERTEX PHARMACEUTICALS INC / MA (VRTX) https://sec-api.dev/companies/vrtx/catalysts |
| Indications | [igan](https://sec-api.dev/indications/igan), [immunoglobulin a nephropathy](https://sec-api.dev/indications/immunoglobulin-a-nephropathy), people with gmg, [gmg](https://sec-api.dev/indications/gmg), pmn, [Myasthenia Gravis, Generalized](https://sec-api.dev/indications/myasthenia-gravis-generalized), [Primary Membranous Nephropathy](https://sec-api.dev/indications/primary-membranous-nephropathy) |
| Modality | fusion_protein |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### 2025: interim data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-02-10, last confirmed 2025-02-10.
- Press release filed with the SEC (EX-99) (accession 0000875320-25-000029): "Vertex expects to complete enrollment in the interim analysis cohort in 2025 and apply for potential accelerated approval in the U.S. after this cohort reaches 36 weeks of treatment, assuming a positive interim analysis." https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/ex-991_q42024.htm

### late 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-03, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0000875320-25-000230): "— R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete; on track to submit first module of povetacicept IgAN BLA to FDA by end of 2025 —" https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm
- Press release filed with the SEC (EX-99) (accession 0000875320-25-000230): "Vertex is on track to submit the first module of the IgAN BLA to the FDA before the end of 2025 and plans to complete the full BLA submission in the first half of 2026 for potential accelerated approval in the U.S. Vertex has now also completed full enrollment of the Phase 3 study in IgAN." https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 2/3.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001704292-26-000014): "•Povetacicept (APRIL/BAFF): In December 2025, Zai Lab joined the global pivotal Phase 2/3 OLYMPUS study in primary membranous nephropathy (pMN) and dosed the first patient in mainland China." https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-12, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000875320-26-000034): "Vertex remains on track to release interim analysis data in the first half of 2026 and also complete the submission in the first" https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm
- Press release filed with the SEC (EX-99) (accession 0001704292-26-000014): "•IgA Nephropathy (IgAN): Zai Lab partner Vertex remains on track to release interim analysis data of the global Phase 3 RAINIER study in the first half of 2026 and also complete the submission in the first half of 2026, if data from the interim analysis are supportive." https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001704292-26-000014): "Zai Lab plans to present an initial data readout from the Phase 1b portion in the first half of 2026, complete enrollment for the Phase 2 portion, and advance the program into the registrational stage within the year." https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm

### 1H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: gMG.
- First seen 2025-05-06, last confirmed 2026-02-13.
- Press release filed with the SEC (EX-99) (accession 0000875320-26-000034): "•Vertex expects to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG in the first half of 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm
- SEC Form 10-K (accession 0000875320-26-000056): "We expect to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept clinical trial evaluating povetacicept for the treatment of people with gMG in the first half of 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm
- SEC Form 10-Q (accession 0000875320-25-000216): "We expect to initiate the Phase 2/3 trial evaluating povetacicept in people with pMN by the end of 2025." https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm
- SEC Form 10-Q (accession 0000875320-25-000192): "We expect to initiate a single, adaptive Phase 2/3 clinical trial of povetacicept vs. standard-of-care in 2025, and the selected dose will be advanced to Phase 3." https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm

### Mar 2026: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031624): "-IgA nephropathy (IgAN): In March 2026, Zai Lab partner Vertex announced positive data from a pre-specified Week 36 interim analysis of the global Phase 3 RAINIER trial of pove in IgA nephropathy (IgAN)." https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-202657x8kex991.htm
- SEC Form 10-Q (accession 0001628280-26-031626): "◦IgAN: In March 2026, our partner Vertex announced positive data from a pre-specified Week 36 interim analysis of the global Phase 3 RAINIER trial of pove in IgAN." https://www.sec.gov/Archives/edgar/data/1704292/000162828026031626/zlab-20260331.htm

### Jun 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: immunoglobulin A nephropathy.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053791): "•Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm
- SEC Form 10-Q (accession 0001628280-26-053793): "•Povetacicept (Pove, Anti-APRIL/BAFF): In June 2026, our partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with IgAN, with a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm

### late 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2/3.
- First seen 2026-02-13, last confirmed 2026-02-13.
- SEC Form 10-K (accession 0000875320-26-000056): "•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development, support regulatory filings, or accelerate regulatory approval, including our plans to complete the full submission for potential accelerated approval of povetacicept in IgAN in the first half of 2026 and to share data from the interim analysis of the Phase 2/3 clinical trial of inaxaplin in AMKD in late 2026 or early" https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm

### November 30, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: immunoglobulin A nephropathy.
- First seen 2026-08-03, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0000875320-26-000287): "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm
- Press release filed with the SEC (EX-99) (accession 0000875320-26-000256): "•The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm
- SEC Form 10-Q (accession 0000875320-26-000291): "•The biologics license application for accelerated approval of povetacicept for adults with IgAN is under priority review by the FDA, with an assigned PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm
- SEC Form 10-Q (accession 0000875320-26-000291): "FDA's review of our biologics license application for accelerated approval of povetacicept with an assigned PDUFA target action date of November 30, 2026;" https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm
- SEC Form 10-Q (accession 0000875320-26-000259): "•The FDA accepted our biologics license application for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053791): "•Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm
- SEC Form 10-Q (accession 0001628280-26-053793): "•Povetacicept (Pove, Anti-APRIL/BAFF): In June 2026, our partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with IgAN, with a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-459293): "The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1798749/000119312526459293/ck0001798749-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-341242): "The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/ck0001798749-20260630.htm

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07890909

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07890909

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Primary Membranous Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07204275

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Primary Membranous Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07204275

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myasthenia Gravis, Generalized.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07501702

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myasthenia Gravis, Generalized.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07501702

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07807995

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT07807995

## Same indication

- [ALXN1920](https://sec-api.dev/pdufa/alxn1920) (AZN)
- [Budoprutug](https://sec-api.dev/pdufa/budoprutug) (CLYM)
- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)
- [Descartes-08](https://sec-api.dev/pdufa/descartes-08) (RNAC)
- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [JADE-001](https://sec-api.dev/pdufa/jade101) (JBIO)
- [Sefaxersen](https://sec-api.dev/pdufa/sefaxersen) (IONS)
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig) (AZN)
- [BRUKINSA® (zanubrutinib)](https://sec-api.dev/pdufa/zanubrutinib) (ONC)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/povetacicept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Povetacicept PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/povetacicept

```bibtex
@misc{secapidev_pdufa_povetacicept_20261116,
  title        = {Povetacicept PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/povetacicept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_povetacicept_20261116","title":"Povetacicept PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/povetacicept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
